HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – GlobeNewswire

| Source: ReportLinker ReportLinker
Lyon, FRANCE
New York, Oct. 05, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape” – https://www.reportlinker.com/p06326010/?utm_source=GNW
– In 2022, there will be more than one million incidence cases of HER2- BC across 16 pharmaceutical markets.
– There are several marketed innovator drugs for the treatment of HER2- BC, mostly kinase inhibitors.
– A total of seven pipeline drugs for HER2- BC are in pre-registration phase and 42 drugs are in Phase III.
– Commercial sponsors dominate clinical trial development in HER2- BC, with the US emerging as the key country for conducting Phase III trials in HER2- BC.
– Partnership was the most common type of deal in North America and Europe, while licensing agreements were the most prominent deal type in South America and Africa.
– Within the next 24 months, several new product launches within HER2- Breast Cancer space are expected.

Scope
HER2- Breast Cancer Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include –
– Disease Landscape
– Disease Overview
– Epidemiology Overview
– Treatment Overview
– Marketed Products Assessment
– Breakdown by Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Pricing and Reimbursement Assessment
– Retail or Manufacturer Price of Products
– Time to Pricing and Time to Reimbursement
– Pipeline Assessment
– Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
– Product Profiles with Sales Forecast
– Late-to-mid-stage Pipeline Drugs
– Phase Transition Success Rate and Likelihood of Approval
– Clinical Trials Assessment
– Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
– Enrolment Analytics, Site Analytics, Feasibility Analysis
– Deals Landscape
– Mergers, Acquisitions, and Strategic Alliances by Region
– Overview of Recent Deals
– Commercial Assessment
– Key Market Players
– Future Market Catalysts

Reasons to Buy
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the HER2- Breast Cancer market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HER2- Breast Cancer market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Read the full report: https://www.reportlinker.com/p06326010/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________

source

Add a Comment

Your email address will not be published. Required fields are marked *